Marks D C, Belov L, Davey M W, Davey R A, Kidman A D
Neurobiology Unit, School of Biological and Biomedical Sciences, University of Technology, Sydney, Gore Hill, N.S.W., Australia.
Leuk Res. 1992 Dec;16(12):1165-73. doi: 10.1016/0145-2126(92)90114-m.
The MTT cell viability assay is widely used in determining drug sensitivity profiles for patients with hematological malignancies and in primary screening of potential chemotherapeutic drugs. Because the multidrug resistance (MDR) phenotype is associated with these malignancies, and since many vital dyes are effluxed from MDR expressing cells, we have investigated whether the MDR phenotype interferes with the MTT assay. In CCRF-CEM and K562 human leukemic cell lines and drug-resistant sub-lines developed from them, comparison of the MTT assay with other cell viability assays showed significant variation in IC50 concentrations, although the resistance relative to the sensitive parent cell was correlated. Inclusion of verapamil, an inhibitor of drug efflux activity, had no effect on the MTT assay.
MTT细胞活力测定法广泛应用于确定血液系统恶性肿瘤患者的药物敏感性谱以及潜在化疗药物的初步筛选。由于多药耐药(MDR)表型与这些恶性肿瘤相关,且许多活性染料会从表达MDR的细胞中流出,我们研究了MDR表型是否会干扰MTT测定法。在CCRF-CEM和K562人白血病细胞系以及由它们衍生出的耐药亚系中,MTT测定法与其他细胞活力测定法的比较显示,IC50浓度存在显著差异,尽管相对于敏感亲本细胞的耐药性是相关的。加入药物外排活性抑制剂维拉帕米对MTT测定法没有影响。